The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II clinical trial on intratumoral autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) plus ipilimumab (IPI) and synthetic adjuvant AS01B combined with low-dose intravenous (IV) nivolumab (NIVO) in advanced pretreated melanoma patients.
 
Cleo Bertels
Travel, Accommodations, Expenses - AstraZeneca; Miltenyi Biotec; MSD
 
Iris Dirven
Travel, Accommodations, Expenses - Merck; Pierre Fabre
 
Manon Vounckx
No Relationships to Disclose
 
Ivan Van Riet
No Relationships to Disclose
 
Ann De Becker
Consulting or Advisory Role - BMS (Inst); Daiichi Sankyo Europe GmbH (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); SOBI (Inst); Takeda (Inst)
 
Bart Neyns
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre